The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer.
Neuroendocrine prostate cancer (NEPC) is the most lethal prostatic neoplasm. NEPC is thought to originate from the transdifferentiation of AR-positive adenocarcinoma cells. We have previously shown that an epigenetic/noncoding interactome (ENI) orchestrates cancer cells' plasticity, thereby allowing the emergence of metastatic, drug-resistant neoplasms. The primary objective of this manuscript is to discuss evidence indicating that some components of the ENI (Polycomb genes, miRNAs) play a key role in NEPC initiation and progression. Long noncoding RNAs represent vast and largely unexplored component of the ENI. Their role in NEPC has not been investigated. We show preliminary evidence indicating that a lncRNA (MIAT) is selectively upregulated in NEPCs and might interact with Polycomb genes. Our results indicate that long noncoding RNAs can be exploited as new biomarkers and therapeutic targets for NEPC.
Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.|Department of Life Health & Chemical Sciences, The Open University, Milton Keynes, UK.
Francesco
F
Crea
Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.
Erik
E
Venalainen
Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.|Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Xinpei
X
Ci
Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.|Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Hongwei
H
Cheng
Genetics Unit, Integrative Oncology, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.
Larissa
L
Pikor
Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.
Abhijit
A
Parolia
Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.
Hui
H
Xue
Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.
Nur Ridzwan
NR
Nur Saidy
Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.|Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Dong
D
Lin
Genetics Unit, Integrative Oncology, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.
Wan
W
Lam
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Colin
C
Collins
Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.|Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Yuzhuo
Y
Wang
D014408:Biomarkers, Tumor / Q000502:physiology*; D054338:Cell Transdifferentiation; D044127:Epigenesis, Genetic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D018358:Neuroendocrine Tumors / Q000235:genetics* / Q000378:metabolism; D063146:Polycomb-Group Proteins / Q000235:genetics / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism; D062085:RNA, Long Noncoding / Q000502:physiology*
D014408:Biomarkers, Tumor; C517383:Miat long non-coding RNA; D063146:Polycomb-Group Proteins; D062085:RNA, Long Noncoding
MIAT; Polycomb; epigenetic/noncoding interactome; long noncoding RNAs; neuroendocrine prostate cancer; transdifferentiation